Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Blood (2019) 134 (Supplement_1): 1540.

https://doi.org/10.1182/blood-2019-131367

Published: 2019

Journal Articles

Four Cycles of Standard Bortezomib and Dexamethasone Produce Significant Overall Response Rates In Patients with Relapsed/Refractory Multiple Myeloma

Harsha Trivedi, RN, PhD, Blanche Mavromatis, MD, Usha Sree Chamarthy, MD, Anas Al-Janadi, MD, Vicki Gilreath, RN, Gordan Srkalovic, MD, PhD

Blood (2010) 116 (21): 5046.

https://doi.org/10.1182/blood.V116.21.5046.5046

Published: 2010

Journal Articles

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Aleksandr Lazaryan, MD, MPH, PhD, Rachid Baz, MD, Mohamad A Hussein, Jr, MD, Paul Elson, ScD, Beth Faiman, CNP, Becky Habecker, Mary Ann Karam, RN, Janice Reed, RN, Kimberly Hamilton, RN, Kellie Bruening, Gordan Srkalovic, MD, PhD, Steven Andresen, DO, Matt Kalaycio, MD, John William Sweetenham, MD, FRCP, Ronald Sobecks, MD, Robert Dean, MD, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Frederic J. Reu, MD

Blood (2010) 116 (21): 1967.

https://doi.org/10.1182/blood.V116.21.1967.1967

Published: 2010

Journal Articles

Phase II Pilot Study of Rituximab + CHOP in Patients with Newly Diagnosed Waldenström’s Macroglobulinemia, an Eastren Cooperative Oncology Group Trial (Study E1A02).

Rafat Abonour, MD, Lijun A. Zhang, MD, Vincent Rajkumar, PhD, Gordan Srkalovic, MD, PhD, Philip R. Greipp, MD, Rafael Fonseca, MD, Morie Gertz, MD

Blood (2007) 110 (11): 3616.

https://doi.org/10.1182/blood.V110.11.3616.3616

Published: 2007

Journal Articles

Arsenic Trioxide (Trisenox® ATO), Ascorbic Acid (AA) and Dexamethasone (Dex) Pulses (TAD) for Relapsed Refractory Progressive Multiple Myeloma (MM) Patients (pts); a Final Report.

Rony M. Abou-Jawde, MD, Janice Reed, RN, Megan Kelly, Luba Platt, BS, Mary Ann Karam, RN, Mary Ruth Kovak, MSN, MBA, Gordan Srkalovic, MD, PhD, Mohamad A. Hussein, MD

Blood (2004) 104 (11): 2419.

https://doi.org/10.1182/blood.V104.11.2419.2419

Published: 2004

Journal Articles

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

Mohamad A. Hussein, MD, Mary Ann Karam, RN, Catherine Brand, Greg L. Pearce, Janice Reed, RN, Kellie Bruening, Paul Sartori, Gordan Srkalovic, MD, PhD, Marta Olesnyckyj, RN, Robert Knight, MD, Kathe Balinski, RN, MA, Jerome Zeldis, MD, PhD

Blood (2004) 104 (11): 208.

https://doi.org/10.1182/blood.V104.11.208.208

Published: 2004

NARROW

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Four Cycles of Standard Bortezomib and Dexamethasone Produce Significant Overall Response Rates In Patients with Relapsed/Refractory Multiple Myeloma

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Phase II Pilot Study of Rituximab + CHOP in Patients with Newly Diagnosed Waldenström’s Macroglobulinemia, an Eastren Cooperative Oncology Group Trial (Study E1A02).

Arsenic Trioxide (Trisenox® ATO), Ascorbic Acid (AA) and Dexamethasone (Dex) Pulses (TAD) for Relapsed Refractory Progressive Multiple Myeloma (MM) Patients (pts); a Final Report.

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

Email alerts

ASH Publications

American Society of Hematology

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Four Cycles of Standard Bortezomib and Dexamethasone Produce Significant Overall Response Rates In Patients with Relapsed/Refractory Multiple Myeloma

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Phase II Pilot Study of Rituximab + CHOP in Patients with Newly Diagnosed Waldenström’s Macroglobulinemia, an Eastren Cooperative Oncology Group Trial (Study E1A02).

Arsenic Trioxide (Trisenox® ATO), Ascorbic Acid (AA) and Dexamethasone (Dex) Pulses (TAD) for Relapsed Refractory Progressive Multiple Myeloma (MM) Patients (pts); a Final Report.

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only